Please ensure Javascript is enabled for purposes of website accessibility

Citron Research Goes After Inovio Pharmaceuticals

By Prosper Junior Bakiny - Mar 10, 2020 at 2:03PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The activist short-seller is highly skeptical about the biotech's claims regarding its ongoing development of a coronavirus vaccine.

The COVID-19 epidemic looks increasingly likely to become a pandemic, but a number of biotech companies are racing to develop vaccines that can protect people against SARS-CoV-2, the coronavirus that causes it. One of these companies is Inovio Pharmaceuticals (INO 6.08%), which famously crafted its first vaccine candidate for the novel coronavirus in a mere three hours, at least according to CEO J. Joseph Kim. 

Shares of Inovio have been red hot over the past month or so, a stock performance that it can credit to investors' faith that one of its vaccines will prove effective against the rapidly spreading virus. However, not everyone believes that Inovio was able to create INO-4800 (its candidate vaccine) so rapidly. The well-known short-seller Citron Research recently tweeted that the claim that Inovio had produced INO-4800 in three hours "ludicrous and dangerous."

Citron Research then went even further, warning investors that the stock would fall back to $2, and called for the Securities and Exchange Commission to investigate Inovio and suspend trading of its stock. Inovio's shares plunged by more than 30% on the heels of Citron Research's tweet. However, even after that sharp decline, the company's shares are up by 140% year to date, which compares quite favorably to the S&P 500's 13.6% loss thus far in 2020. 

Two fists with boxing gloves hitting each other.

Image Source: Getty Images.

Inovio responds to Cintron Research 

The biotech company sent out a tweet of its own to reassure investors, dismissing Citron Research as a third-party that had "demonstrated a lack of understanding of the science behind DNA medicines."  Inovio also reaffirmed its claim that it had created a potential vaccine for COVID-19 within three hours after the genetic sequence of SARS-CoV-2 was made public. Inovio says it still plans to start human clinical trials of INO-4800 in the U.S. in April. 

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
INO
$2.79 (6.08%) $0.16

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/15/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.